Please select the eligibility criteria that correspond to the clinical trial below.
Title: Behavior Enhances Drug Reduction of Incontinence
Brief Summary: The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.


Options:
A: Inclusion Criteria:

* Urgency urinary incontinence or mixed urinary incontinence, established via telephone interview
* Urinary leakage twice a week or more often
* Duration of urinary leakage with urgency for at least 12 months
* Ability to read and write Swedish
* Asset to a smartphone (minimum iOS\* 8.0 for Apple, 4.0.3 for Androids
* Possibility to send and receive email and asset to printer
* Motivation and time to perform a 15 weeks long treatment programme with focus on self-care and behavioural training (mainly pelvic floor muscle training and bladder training).
* Accept to be randomized to one of two groups; a treatment app group or an information app Group

  * iOS=mobile operating system including iPhone, iPad and iPod touch

Exclusion Criteria:

* Participation in our previous internet or smartphone study
* Ongoing pregnancy
* Former incontinence surgery
* Known malignancy in lower abdomen
* Unassessed difficulties in emptying bladder
* Visual blood in urine
* Three or more urinary tract infections during the last 12 months
* One or more pyelonephritis during the last three years
* Painful micturition
* Painful urgency
* Intermenstrual bleeding
* Neurological disease such as multiple sclerosis or Parkinsons disease
* Previous stroke
* Diabetes mellitus
* Maximum voided volume of less than 150 ml (micturition chart)
* Regular use of any mobile app for pelvic floor muscle training during the last month
* Usage of antimuscarinic drugs or mirabegron during the last month
B: Inclusion Criteria:

* Male
* Community-dwelling
* Veteran
* Self-reported urgency
* Self-reported frequent urination
* Mean of \> 8 voids per 24-hour day on bladder diary
* Able to come to clinic

Exclusion Criteria:

* Urologic surgery in the past 6 months
* Nonambulatory (unless has independent transfer skills)
* Flow rate \< 5mL at baseline and \< 10mL/sec after run-in (on simple uroflowmetry)
* Post-void residual urine volume \> 250mL at baseline and \> 150mL after run-in (on bladder ultrasound)
* Continual leakage
* Urinary tract infection (growth of \> 100,000 colonies per ml of a urinary pathogen on urine culture). May be reconsidered after treatment and negative culture.
* Fecal impaction
* Poorly controlled diabetes (glycosylated hemoglobin \>9 within last 3 months)
* Hematuria on microscopic examination in the absence of infection
* Any unstable medical condition (particularly: decompensated congestive heart failure, malignant arrhythmias, unstable angina)

  -- Impaired mental status (\< 24 on Folstein's Mini-Mental State Exam)
* Narrow angle glaucoma
* Gastric retention (by medical history)
* Hypersensitivity to tamsulosin or oxybutynin
* Current use of anticholinergic agents for detrusor instability. May be reconsidered after 2-week wash-out.
* If on diuretic, dose has not been stable for at least three months
* Sleep apnea, unless surgically corrected
C: Inclusion:

* Female
* Urge predominant incontinence
* Incontinent \> 3 mos
* Available for 8 mos of followup

Exclusion:

* Pregnancy or \< 6 mos post-partum
* Hypersensitivity to drug (tolterodine)
* Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple Sclerosis, spinal cord injury)
* History of extensive behavior treatment
D: * Predominant stress urinary incontinence by self-report,examination and test;
* Urethral hypermobility;
* Eligible for both surgical procedures;
* Ambulatory;
* Not pregnant;
* \>12 months post-partum;
* No systemic disease known to affect bladder function;
* No current chemotherapy or radiation therapy;
* No urethral diverticulum, augmentation cytoplasty, or artificial sphincter;
* No recent pelvic surgery;
* Available for follow-up and able to complete study assessments;
* Signed informed consent.

Answer: C